Up to 40% of patients with lung cancer do not respond to a targeted therapy designed to block tumor growth, which is a puzzling clinical setback that researchers have long tried to solve. Now, scientists have discovered why that intrinsic resistance occurs, and they pinpointed a drug they say could potentially reverse it.
Their study, a collaboration between Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute, found that overexpression of the growth protein Cripto-1 makes lung cancer cells resistant to the drug erlotinib (Tarceva®). Experiments in cell lines and in animals demonstrated that blocking Cripto-1 signaling transduction restored sensitivity to the drug, one of a number of epidermal growth factor receptor (EGFR) inhibitors used in non-small cell lung carcinoma and other cancers.
The drug they used is a Src inhibitor, because Cripto-1 activates the oncogenic tyrosine-protein kinase Src. Although the specific drug they used is no longer available, at least one similar Src inhibitor has been approved by the U.S. Food and Drug Administration for treatment of chronic myelogenous leukemia.
Continue Reading
“This is a welcome finding because Cripto-1 belongs to a family of proteins that can be targeted by drugs that have already been developed,” said the study’s senior investigator, Giuseppe Giaccone, MD, PhD, associate director for clinical research at Georgetown Lombardi in Washington, DC. The study was published in the Journal of Clinical Investigation (2014; doi:10.1172/JCI73048).
Giaccone said that Georgetown Lombardi is preparing a clinical trial to see if what they observed in the laboratory will work in patients. The trial will test a combination of erlotinib and a Src inhibitor (AZD0424) in patients with non-small cell lung cancer. They will select patients whose cancer cells harbor a mutation in their EGFR because these patients are most sensitive to erlotinib.
“There has been very little investigation when a person never responds to an EGFR inhibitor—most research has been done on acquired resistance that occurs after the drug has shown some benefit,” he said.
“Most patients using erlotinib exhibit either intrinsic or acquired resistance, so we frankly don’t cure anyone with the drug, although we can extend lifespan,” Giaccone said. “So if we can understand what is limiting the activity of the drug up front, I believe treatment of patients can be vastly improved.”
